The Clorox Company (NYSE:CLX) Shares Bought by Mackenzie Financial Corp

Mackenzie Financial Corp lifted its stake in The Clorox Company (NYSE:CLX - Free Report) by 30.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,464 shares of the company's stock after purchasing an additional 3,148 shares during the quarter. Mackenzie Financial Corp's holdings in Clorox were worth $2,187,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Clorox in the 4th quarter worth $259,041,000. FMR LLC grew its holdings in shares of Clorox by 75.4% in the fourth quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after purchasing an additional 585,526 shares during the period. Marshall Wace LLP increased its position in Clorox by 549.8% during the fourth quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock worth $88,144,000 after purchasing an additional 459,203 shares during the last quarter. ExodusPoint Capital Management LP raised its stake in Clorox by 187.9% during the fourth quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock worth $113,508,000 after purchasing an additional 456,114 shares during the period. Finally, Man Group plc boosted its holdings in Clorox by 154.6% in the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock valued at $92,655,000 after purchasing an additional 346,449 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

Insider Transactions at Clorox

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, with a total value of $546,280.00. Following the transaction, the director now owns 4,000 shares of the company's stock, valued at approximately $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.57% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Evercore ISI set a $140.00 price objective on Clorox and gave the stock an "underperform" rating in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. UBS Group decreased their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Citigroup dropped their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a report on Monday, April 14th. Finally, Wells Fargo & Company decreased their price target on Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $151.23.

Clorox Stock Performance

Shares of Clorox stock traded down $0.32 on Wednesday, hitting $129.77. The stock had a trading volume of 1,155,297 shares, compared to its average volume of 1,344,051. The stock has a market cap of $15.99 billion, a price-to-earnings ratio of 35.46, a P/E/G ratio of 2.62 and a beta of 0.60. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The Clorox Company has a 52-week low of $129.03 and a 52-week high of $171.37. The company's 50 day moving average price is $137.40 and its 200 day moving average price is $150.49.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. During the same period last year, the firm earned $1.71 EPS. The company's quarterly revenue was down 8.0% on a year-over-year basis. On average, research analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.